Mavacamten

CAS No.:1642288-47-8

Mavacamten is a white to off-white crystalline solid with the molecular formula C₁₅H₁₉N₃O₂ and a molecular weight of approximately 273.33 g/mol. It is a selective, allosteric, and reversible inhibitor of cardiac myosin ATPase, acting by reducing the formation of actin-myosin cross-bridges and shifting the overall myosin population toward an energy-sparing super-relaxed state. The compound exhibits an oral bioavailability of approximately 85%, reaches peak plasma concentration within 1 to 2 hours, and has a mean elimination half-life of about 8 days. Mavacamten is primarily metabolized by CYP2C19 and, to a lesser extent, by CYP3A4. It is supplied as oral hard capsules in dosage strengths of 2.5 mg, 5 mg, 10 mg, and 15 mg.

Core Functions:

• Active pharmaceutical ingredient (API) in Camzyos® for treating adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy

• Research use in cardiac sarcomere biology and hypertrophic cardiomyopathy pathophysiology studies

• Investigational use in adolescent patients with obstructive HCM (Phase 3 SCOUT-HCM trial completed) 

• Clinical applications in patients eligible for septal reduction therapy (as shown in VALOR-HCM trial) 

• Reference standard for analytical method development and quality control in pharmaceutical testing